Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Updated results from phase III EXTEND clinical trial of pixantrone released

Cell Therapeutics, Inc. ("CTI") announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London during a session at the 2009 American Society of Hematology ("ASH") Annual Meeting updated results from the pivotal phase III EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive non-Hodgkin's lymphoma ("NHL") patients who have failed 2 or more prior therapies.

7 Dec 2009

ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today updated clinical data showing that Omapro™ (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

7 Dec 2009

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Gloucester Pharmaceuticals announced today the presentation of preclinical data demonstrating that the combination of ISTODAX® (romidepsin) and Velcade® (bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin's lymphoma cell lines.

7 Dec 2009

Poster summarizing clinical trial data regarding SB-743921 presented by Cytokinetics

Cytokinetics, Incorporated announced today that a poster summarizing clinical trial data regarding SB-743921 was presented at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

7 Dec 2009

VELCADE based regimens are cost-effective for payers and patients, finds study

Millennium: The Takeda Oncology Company today announced that two studies presented at the 51st American Society of Hematology (ASH) Annual Meeting found that VELCADE based regimens are more cost-effective for payers and reduced out-of-pocket costs for patients than other commonly used multiple myeloma treatments.

7 Dec 2009

McKesson to introduce PROmanager-Rx system at the 44th Midyear Clinical Meeting and Exhibition

McKesson today will introduce the PROmanager-Rx™ system, an innovative solution that enables hospitals for the first time to fully automate the dispensing of tablets, capsules, and other oral solid medications that come pre-packaged from drug manufacturers in unit-dose, bar-coded form.

7 Dec 2009

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

7 Dec 2009

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).

7 Dec 2009

Amgen announces results from three studies on the safety and efficacy of Nplate

Amgen Inc. today announced results from three studies on the safety and efficacy of Nplate® (romiplostim) in adult patients with myelodysplastic syndromes (MDS).

7 Dec 2009

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Onyx Pharmaceuticals, Inc. today announced updated safety data from the pivotal Phase 2b 003-A1 study, known as the 003 trial, demonstrating that carfilzomib is well-tolerated in heavily pre-treated relapsed and refractory multiple myeloma patients.

7 Dec 2009

Study finds substantial variation in hydroxyurea utilization for sickle cell disease

A new study by researchers from the Medical College of Wisconsin, in Milwaukee, found a substantial variation in hydroxyurea utilization for pain and other sickle cell disease complications in children.

7 Dec 2009

New findings may yield more effective therapies for infants with blood cancer

Pediatric oncologists have identified specific genes, dubbed partner genes, that fuse with another gene to drive an often-fatal form of leukemia in infants. By more accurately defining specific partner genes, researchers expect to better predict which infants may benefit from particular treatments.

7 Dec 2009

Positive final data from Phase 2 study of ISTODAX presented

Gloucester Pharmaceuticals announced today the presentation of positive final data from a Phase 2 study of ISTODAX® (romidepsin) in peripheral T-cell lymphoma (PTCL) conducted by the National Cancer Institute (NCI) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

6 Dec 2009

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

Health experts available to discuss health care reform

Edward D. Miller was named chief executive officer of Johns Hopkins Medicine, the 13th dean of The Johns Hopkins University School of Medicine and vice president for medicine of The Johns Hopkins University in January 1997.

5 Dec 2009

Genomic Health to present its Oncotype DX multi-gene expression test studies at the 32nd SABCS

Genomic Health, Inc. today announced that the company will present results from five studies at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), taking place December 9-13, 2009, at the Henry B. Gonzalez Convention Center.

5 Dec 2009

Partners HealthCare System's series 2009J fixed-rate revenue bonds rated 'AA'

Fitch Ratings has assigned an 'AA' to Partners HealthCare System's approximately $475 million Massachusetts Health and Educational Facilities Authority revenue bonds (Partners HealthCare System), fixed-rate revenue bonds, series 2009J, which are expected to be sold as two sub series. Fitch also affirms its 'AA' long-term rating on all of Partners' outstanding debt and affirms its 'F1+' rating on approximately $485 million of Partners HealthCare System's debt that is backed by self-liquidity.

5 Dec 2009

Vermillion files First Amended Plan of Reorganization and Disclosure Statement with the United States Bankruptcy Court

Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) announced that on December 3, 2009, it filed its First Amended Plan of Reorganization and related amended Disclosure Statement with the United States Bankruptcy Court for the District of Delaware.

5 Dec 2009

'Twist' gene plays a key role in the development of breast cancer

Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accurately distinguish stem cells that drive aggressive, metastatic breast cancer from other breast cancer cells.

5 Dec 2009

NCI awards $55.4 million, multiple-year contract to Fred Hutchinson Cancer Research Center

The National Cancer Institute has awarded a $55.4 million, multiple-year contract to Fred Hutchinson Cancer Research Center to become the nation's sole operator of its Cancer Information Service Contact Center.

5 Dec 2009

Oncology News and Research

Further Reading

Updated results from phase III EXTEND clinical trial of pixantrone released

ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Poster summarizing clinical trial data regarding SB-743921 presented by Cytokinetics

VELCADE based regimens are cost-effective for payers and patients, finds study

McKesson to introduce PROmanager-Rx system at the 44th Midyear Clinical Meeting and Exhibition

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

Amgen announces results from three studies on the safety and efficacy of Nplate

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Study finds substantial variation in hydroxyurea utilization for sickle cell disease

New findings may yield more effective therapies for infants with blood cancer

Positive final data from Phase 2 study of ISTODAX presented

New treatment options for leukemia and myeloproliferative disorders introduced

Health experts available to discuss health care reform

Genomic Health to present its Oncotype DX multi-gene expression test studies at the 32nd SABCS

Partners HealthCare System's series 2009J fixed-rate revenue bonds rated 'AA'

Vermillion files First Amended Plan of Reorganization and Disclosure Statement with the United States Bankruptcy Court

'Twist' gene plays a key role in the development of breast cancer

NCI awards $55.4 million, multiple-year contract to Fred Hutchinson Cancer Research Center

Cancer Research eBook

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Latest News